Lisanti Capital Growth LLC Invests $3.52 Million in Alphatec Holdings, Inc. (NASDAQ:ATEC)

Lisanti Capital Growth LLC bought a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 347,280 shares of the medical technology company's stock, valued at approximately $3,521,000. Lisanti Capital Growth LLC owned 0.24% of Alphatec as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rhumbline Advisers raised its stake in shares of Alphatec by 1.3% in the fourth quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company's stock worth $1,277,000 after buying an additional 1,746 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Alphatec by 119.3% in the 4th quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company's stock worth $6,079,000 after purchasing an additional 360,258 shares during the period. Oppenheimer Asset Management Inc. bought a new stake in Alphatec in the fourth quarter worth about $106,000. Charles Schwab Investment Management Inc. boosted its position in Alphatec by 2.8% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 846,224 shares of the medical technology company's stock valued at $7,768,000 after buying an additional 23,002 shares during the period. Finally, Atria Investments Inc lifted its holdings in shares of Alphatec by 20.3% in the 4th quarter. Atria Investments Inc now owns 23,585 shares of the medical technology company's stock worth $217,000 after buying an additional 3,976 shares during the period. 66.35% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have recently issued reports on ATEC. Lake Street Capital upgraded Alphatec to a "buy" rating and set a $18.00 price objective for the company in a research note on Monday, June 16th. Needham & Company LLC restated a "buy" rating and issued a $16.00 target price on shares of Alphatec in a report on Friday, May 2nd. Piper Sandler restated an "overweight" rating and set a $15.00 price target (up previously from $13.00) on shares of Alphatec in a report on Friday, May 2nd. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Alphatec in a research report on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, Alphatec has an average rating of "Moderate Buy" and an average price target of $17.89.

Insiders Place Their Bets

In related news, EVP Craig E. Hunsaker sold 13,878 shares of Alphatec stock in a transaction on Thursday, June 5th. The shares were sold at an average price of $12.36, for a total transaction of $171,532.08. Following the sale, the executive vice president owned 1,450,018 shares of the company's stock, valued at $17,922,222.48. The trade was a 0.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Scott Lish sold 22,727 shares of the company's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $11.07, for a total transaction of $251,587.89. Following the completion of the sale, the chief operating officer owned 748,918 shares in the company, valued at approximately $8,290,522.26. This trade represents a 2.95% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 294,065 shares of company stock worth $3,633,172. Corporate insiders own 22.80% of the company's stock.

Alphatec Price Performance

Shares of ATEC traded up $0.02 during mid-day trading on Monday, hitting $11.10. 1,784,928 shares of the company's stock were exchanged, compared to its average volume of 1,657,165. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $13.14. The business's 50 day moving average is $11.88 and its two-hundred day moving average is $10.91.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 25.77%. The business had revenue of $169.18 million for the quarter, compared to analysts' expectations of $167.57 million. During the same period last year, the company posted ($0.34) earnings per share. The business's quarterly revenue was up 22.2% on a year-over-year basis. On average, equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.